Skip to main content

Table 3 IR and HR of CKD/ESRD associated with duration of SGLT2i use among patients with DM

From: Risk of CKD among patients with DM taking diuretics or SGLT2i: a retrospective cohort study in Taiwan

Days

Event

PY

IR

aHR (95% CI)

None

139

7,292

19.06

1 (Reference)

 

90–196

29

1,346

21.54

1.17 (0.78, 1.75)

1 (Reference)

197–448

43

3,632

11.84

0.61 (0.43, 0.86)**

0.52 (0.33, 0.84)**

≥ 448

3

2,563

1.17

0.06 (0.02, 0.18)***

0.05 (0.01, 0.16)***

  1. aHR, adjusted hazard ratio; CKD, chronic kidney disease; days, SGLT2i use duration; ESRD, end-stage renal disease; event, number of patients with CKD; IR, incidence rate (per 1000 person-years); PY, person-years; SGLT2i, sodium-glucose cotransporter-2 inhibitors; *p < 0.05, **p < 0.01, ***p < 0.001
Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us